Tirzepatide (30mg)

Tirzepatide is supplied as a catalogued research material in 10mg, 20mg and 30mg.

“Tirzepatide” is a catalogue alias, not a chemical identity. Tirzepatide is a modified GIP-derived peptide and dual GIP/GLP-1 receptor agonist; GLP-2 is a different endogenous 33-residue hormone. Registry assignment requires confirmation of the complete modified structure and batch form [1–3].

Chemical properties and registry information

Registry values apply only to the specific molecular entity, sequence, termini and material form. Batch records take precedence over family-level literature identifiers.

Tirzepatide is a dual GIP and GLP-1 receptor agonist, not a GLP-2 agonist. It is used for type 2 diabetes and weight management.

Research background and published evidence

Published research

Defined Tirzepatide reference material can support structural confirmation, impurity profiling, receptor-pharmacology research and analytical-method development. That research context requires exact modified-peptide identity and does not make a catalogue vial equivalent to a separately manufactured medicinal product [1,3].

Current scientific understanding

Clinical evidence and authorization for branded Tirzepatide medicines are formulation-, strength-, indication- and manufacturer-specific. They do not establish identity, purity, bioequivalence, safety, efficacy, dosage, administration or authorization for this catalogue material [3,4].

Tirzepatide is the active substance in the prescription medicine Mounjaro. A research-use label does not confer medicine authorization or permit unapproved human supply; FDA specifically warns about unapproved Tirzepatide products and products falsely labelled “for research purposes.” Do not imply equivalence to Mounjaro or any authorised product [3,4].

Technical comparison

Quality and testing

Quality information is batch- and presentation-specific. Use only the report linked to the exact size and lot. A report listed for another size, lot or similarly named material must not be treated as evidence for this product.

Chromatographic area purity, identity, net peptide or analyte content, water or counter-ion content, sterility, endotoxin and elemental impurities are different measurements. One result does not establish the others. Only tests supported by a visible, matching report should be regarded as available.

Laboratory handling and storage

Store and handle only under the conditions stated on the product label, batch CoA and SDS. Keep the container secured, correctly identified and protected from contamination. Do not infer storage, solvent compatibility or stability from a related compound.

Laboratory preparation, analytical-method selection, risk assessment, personal protective equipment and waste disposal should follow the applicable SDS and the institution's approved procedures.

Regulatory and legal status

Sources and references

1. [1] PubChem. Tirzepatide structure and registry record, CID 156588324.
2. [2] IUPHAR/BPS Guide to Pharmacology. GLP-2 structure: distinct endogenous 33-residue peptide.
3. [3] European Medicines Agency. Mounjaro: authorised prescription Tirzepatide medicinal product.
4. [4] U.S. FDA. Concerns with unapproved GLP-1 drugs, including false research-use labelling.

Frequently Asked Questions

Do the CAS number and PubChem CID apply to every batch form?

Only when the exact sequence or structure, termini, conjugation, salt or counter-ion and hydration state match. The batch CoA and SDS govern; a related-compound identifier must not be substituted.

What does an analytical purity result mean?

It is method- and report-specific. For example, an HPLC area percentage is not automatically the same as identity, net content, sterility, endotoxin status or absence of elemental impurities.

How should the material be stored and handled?

Follow the exact label, batch CoA and SDS together with the institution's risk assessment. Use only storage and stability information linked to the exact material form and batch.